ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of the Bilateral TAP Block Versus Curare in Muscle Relaxation of the Abdominal Wall During Laparoscopic Digestive Surgery: Prospective Randomized Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01628952
Recruitment Status : Completed
First Posted : June 27, 2012
Last Update Posted : March 20, 2013
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire, Amiens

Brief Summary:
This is a Biomedical Research, prospective, randomized, controlled single-blind mono centric, phase IV comparison trial of the bilateral TAP block versus curare in muscle relaxation of the abdominal wall during laparoscopic digestive surgery.

Condition or disease Intervention/treatment Phase
The Main of This Study is to Compare the Nerve Block of the Muscles of the Abdominal Wall Between the Bilateral TAP Block and Curare Drug: Transversus Abdominis Plane Drug: Curare Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Comparison of the Bilateral Transversus Abdominis Plane (TAP) Block Versus Curare in Muscle Relaxation of the Abdominal Wall During Laparoscopic Digestive Surgery: Prospective Randomized Study
Study Start Date : June 2012
Actual Primary Completion Date : January 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Curare
U.S. FDA Resources

Arm Intervention/treatment
Experimental: TAP Drug: Transversus Abdominis Plane
PIA coelioscopic
Active Comparator: curare
Patients will be randomized into two parallel groups. One group will receive curare, another benefit of a bilateral TAP block
Drug: Curare
IAP coelioscopic



Primary Outcome Measures :
  1. Muscle relaxation. [ Time Frame: 20 minutes after anesthesia induction ]
    Muscle relaxation of the abdominal wall will be evaluated based on the amount of volume infused initially to create the pneumoperitoneum. This parameter is given by the unit of laparoscopy and allow us to calculate the abdominal compliance (C = ΔV / Ap).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients older than 18 years and under 75 years
  • Informed consent signed
  • ASA I, II and III
  • Patient affiliated to social security

Exclusion Criteria:

  • ASA IV

    • BMI> 35 kg / m
    • Personal or family history of malignant hyperthermia
    • History of allergy or hypersensitivity to intravenous anesthetics (remifentanil), local anesthetics or muscle relaxants
    • Contraindications to sevoflurane: a history of malignant hyperthermia, history of liver disease after sevoflurane anesthesia, halogenated agents or hypersensitivity to any of these components.
    • Contraindications to succinylcholine: hyperkalemia, plasma cholinesterase deficiency nickname, para or tetraplegia more than 24 hours, burns over 24
    • Contraindications to cisatracurium: myasthenia
    • Neuromuscular diseases
    • Contraindications to local anesthetics: hypersensitivity to local anesthetics of the amide, intravenous regional anesthesia, porphyria, ventricular atrial conduction disturbances, epilepsy uncontrolled by treatment
    • Pregnancy and lactation
    • severe coagulation disorders
    • Inability to understand and give informed consent
    • Patient under guardianship, curatorship or protected
    • Indication of use of a hypnotic ketamine (BIS change)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01628952


Locations
France
CHU Amiens
Amiens, Picardie, France, 80054
Sponsors and Collaborators
Centre Hospitalier Universitaire, Amiens
Investigators
Study Director: Hervé DUPONT, PU-PH CHU Amiens France

Responsible Party: Centre Hospitalier Universitaire, Amiens
ClinicalTrials.gov Identifier: NCT01628952     History of Changes
Other Study ID Numbers: PI2012_843_0007
2012-000673-23 ( EudraCT Number )
First Posted: June 27, 2012    Key Record Dates
Last Update Posted: March 20, 2013
Last Verified: June 2012

Additional relevant MeSH terms:
Curare
Neuromuscular Nondepolarizing Agents
Neuromuscular Blocking Agents
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action